Sign In
Buy RDHL
$0.93
+0.0860 (+10.24%)
At Close: Jun 23, 2026
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
04:10pm, Monday, 22'nd Jun 2026
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ --
RedHill Biopharma Announces Up To $19.4 Million Private Placement
08:00am, Thursday, 18'th Jun 2026
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- R
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
07:00am, Tuesday, 09'th Jun 2026
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
07:00am, Monday, 08'th Jun 2026
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d
Bessor Announces Entering Option for the Redhill Property
11:23am, Tuesday, 26'th May 2026
Vancouver, BC, May 26, 2026 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) announces that, on February 9, 2026, it entered into an agreement (the “Agreement�
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
08:00am, Monday, 27'th Apr 2026
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partne
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on thera
Analyzing Redhill Biopharma (NASDAQ:RDHL) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
01:24am, Monday, 06'th Apr 2026
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both medical companies, but which is the superior investment? We
Redhill Biopharma (NASDAQ:RDHL) Share Price Crosses Below 200-Day Moving Average – What’s Next?
02:57am, Wednesday, 25'th Mar 2026
Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.27 and traded as
Joint U.S. Commercialization of RedHill's Talicia® Commences
07:00am, Wednesday, 25'th Feb 2026
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and
Redhill Biopharma (NASDAQ:RDHL) Share Price Passes Below 200-Day Moving Average – What’s Next?
04:33am, Thursday, 05'th Feb 2026
Redhill Biopharma Ltd. (NASDAQ: RDHL - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $1.39 and
What's Going On With Redhill Biopharma Stock On Tuesday?
10:26am, Tuesday, 06'th Jan 2026
Redhill Biopharma Ltd (NASDAQ: RDHL) stock is trading lower on Tuesday, possibly on profit-taking after the stock rallied roughly 36% on Monday, as per data from Benzinga Pro.
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
07:00am, Monday, 05'th Jan 2026
RHB-102 1 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis
